C
FDMT icon

Covestor’s 4D Molecular Therapeutics FDMT Stock Holding History

Covestor’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
16
– – ﹤0.01% 2421
2025
Q4 		$0 Hold
16
– – ﹤0.01% 2403
2025
Q3 		$0 Hold
16
– – ﹤0.01% 2433
2025
Q2 		$0 Sell
16
-1
-6% -$4 ﹤0.01% 2376
2025
Q1 		$0 Buy
17
+9
+113% +$42 ﹤0.01% 2385
2024
Q4 		$0 Buy
8
+1
+14% +$8 ﹤0.01% 2396
2024
Q3 		$0 Buy
7
+3
+75% +$50 ﹤0.01% 2380
2024
Q2 		$0 Hold
4
– – ﹤0.01% 2396
2024
Q1 		$0 Buy
+4
New +$102 ﹤0.01% 2393

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Covestor's FDMT Position: Q1 2026 in Review

Covestor held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 16 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

Covestor first reported a position in FDMT in Q1 2024 and has held it in 9 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Covestor held 16 shares of 4D Molecular Therapeutics worth $0 as of Q1 2026.
  • Covestor left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2421 holding.
  • Covestor first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.